SCHEMBL2416635

SCHEMBL2416635

O=c1[nH]c2cc(Cl)c(C(F)(F)F)cc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 6/20 0.45
KMT2A Q03164 3/20 0.45
GRIA2 P42262 2/20 0.45
GRIA3 P42263 2/20 0.45
GRIA4 P48058 2/20 0.45
CYP1A2 P05177 2/20 0.45
GRIN2D O15399 2/20 0.45
GRIN3B O60391 2/20 0.45
GRIN1 Q05586 2/20 0.45
GRIN2A Q12879 2/20 0.45
GRIN2B Q13224 2/20 0.45
GRIN2C Q14957 2/20 0.45
GRIN3A Q8TCU5 2/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL462740 0.88 GRIN2D (0.61) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL30035743 0.84 KDM4E (0.44) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL640124 0.78 GRIA1 (0.70) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL18190563 0.73 GRIA1 (0.73) GRIA1KMT2ACACNG8PDE3BPDE3A
SCHEMBL1439986 0.72 ALDH1A1 (0.63) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL11602223 0.72 NOTUM (0.44) NOTUM
SCHEMBL1192625 0.72 GRIA1 (0.59) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL7787756 0.72 GRIA1 (0.61) GRIA1KMT2AGRIA2GRIA3GRIA4
SCHEMBL22425111 0.70 KDR (0.72) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL16699742 0.70 NOTUM (0.47) TSHRNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026241-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2011-09-27 US disclosed
US-7582761-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-09-01 US disclosed
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS BALAN CHENERA 2009-06-04 US disclosed
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV3, TRPV2 GRIA1 698/4885KMT2A 3344/4885GRIA2 580/4885
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 GRIA1 554/4885KMT2A 3264/4885GRIA2 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.